Ganetespib, under development by Synta, is a small molecule inhibitor of HSP90. HSP90 is a chaperone protein required to drive growth, proliferation, and cell survival in tumor tissue. Many oncogenic proteins rely on HSP90, and the inhibition of this molecule causes the degradation and death of these proteins.
Ganetespib is a small molecule inhibitor of heat-shock protein 90 (hsp90), under development for acute myeloid leukemia (AML). Early Phase I and Phase II studies indicate that ganetespib has a biological effect in AML, but late-stage data are required to fully evaluate patient outcomes. If approved, ganetespib would compete with Boehringer Ingelheim’s pipeline candidate volasertib. Synta Pharmaceuticals should seek a commercial partner in order to effectively compete with Boehringer Ingelheim’s commercial capabilities.
6 Figure 1: Ganetespib – SWOT analysis for AML
7 Figure 2: Datamonitor Healthcare’s drug assessment summary for ganetespib in AML
8 Figure 3: Datamonitor Healthcare’s drug assessment summary for ganetespib in AML
LIST OF TABLES
4 Table 1: Ganetespib drug profile for acute myeloid leukemia
5 Table 2: Summary of clinical trial development of ganetespib in acute myeloid leukemia
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.